Effect of Roflumilast on Systemic Markers of Bone Metabolism and Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease

Trial Profile

Effect of Roflumilast on Systemic Markers of Bone Metabolism and Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 27 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 26 Sep 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016.
    • 26 Sep 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top